Literature DB >> 22922767

Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Mona E E Elfaki1, Eltahir A G Khalil, Anne S De Groot, Ahmed M Musa, Andres Gutierrez, Brima M Younis, Kawthar A M Salih, Ahmed M El-Hassan.   

Abstract

Visceral leishmaniasis (VL) is a serious parasitic disease for which control measures are limited and drug resistance is increasing. First and second generation vaccine candidates have not been successful. The goal of the present study was to select possibly immunogenic L. donovani donovani GP63 peptides using immunoinformatics tools and to test their immunogenicity in vitro. The amino acid sequence of L. donovani donovani GP63 [GenBank accession: ACT31401] was screened using the EpiMatrix algorithm for putative T cell epitopes that would bind to the most common HLA class II alleles (DRB1*1101 and DRB1*0804) among at-risk populations. Four T cell epitopes were selected from nine potential candidates. Stimulation of whole blood from healthy volunteers using the peptides separately produced mean IFN-γ and IL-4 levels that were not significantly different from negative controls, while the pooled peptides produced a moderate IFN-γ increase in some volunteers. However, mean IL-10 levels were significantly reduced for all individuals compared with controls. The immunogenicity of these epitopes may be harnessed most effectively in a vaccine delivered in combination with immune-modulating adjuvants.

Entities:  

Keywords:  EpiMatrix; T cell epitopes; vaccine; visceral leishmaniasis

Mesh:

Substances:

Year:  2012        PMID: 22922767      PMCID: PMC3656064          DOI: 10.4161/hv.21881

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  55 in total

Review 1.  From immunome to vaccine: epitope mapping and vaccine design tools.

Authors:  Anne S De Groot; William Martin
Journal:  Novartis Found Symp       Date:  2003

2.  Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis.

Authors:  E E Zijlstra; A M el-Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2001-04       Impact factor: 2.184

3.  In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma.

Authors:  C L Karp; S H el-Safi; T A Wynn; M M Satti; A M Kordofani; F A Hashim; M Hag-Ali; F A Neva; T B Nutman; D L Sacks
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

4.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

Authors:  G Dranoff; E Jaffee; A Lazenby; P Golumbek; H Levitsky; K Brose; V Jackson; H Hamada; D Pardoll; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 5.  Leishmaniasis: current situation and new perspectives.

Authors:  P Desjeux
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.268

6.  Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.

Authors:  A A Kamil; E A G Khalil; A M Musa; F Modabber; M M Mukhtar; M E Ibrahim; E E Zijlstra; D Sacks; P G Smith; F Zicker; A M El-Hassan
Journal:  Trans R Soc Trop Med Hyg       Date:  2003 May-Jun       Impact factor: 2.184

7.  Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production.

Authors:  G Del Prete; M De Carli; F Almerigogna; M G Giudizi; R Biagiotti; S Romagnani
Journal:  J Immunol       Date:  1993-01-15       Impact factor: 5.422

8.  The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages.

Authors:  D G Russell; H Wilhelm
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

9.  Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major.

Authors:  D M Yang; M V Rogers; F Y Liew
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

10.  The Leishmania receptor for macrophages is a lipid-containing glycoconjugate.

Authors:  E Handman; J W Goding
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

View more
  13 in total

Review 1.  Advances in the study of HLA-restricted epitope vaccines.

Authors:  Lingxiao Zhao; Min Zhang; Hua Cong
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

2.  Identification of Potential MHC Class-II-Restricted Epitopes Derived from Leishmania donovani Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.

Authors:  Manas Ranjan Dikhit; Akhilesh Kumar; Sushmita Das; Budheswar Dehury; Ajaya Kumar Rout; Fauzia Jamal; Ganesh Chandra Sahoo; Roshan Kamal Topno; Krishna Pandey; V N R Das; Sanjiva Bimal; Pradeep Das
Journal:  Front Immunol       Date:  2017-12-14       Impact factor: 7.561

Review 3.  Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

Authors:  Nicky Didwania; Md Shadab; Abdus Sabur; Nahid Ali
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

4.  A Poly(Lactic-co-Glycolic) Acid Nanovaccine Based on Chimeric Peptides from Different Leishmania infantum Proteins Induces Dendritic Cells Maturation and Promotes Peptide-Specific IFNγ-Producing CD8+ T Cells Essential for the Protection against Experimental Visceral Leishmaniasis.

Authors:  Evita Athanasiou; Maria Agallou; Spyros Tastsoglou; Olga Kammona; Artemis Hatzigeorgiou; Costas Kiparissides; Evdokia Karagouni
Journal:  Front Immunol       Date:  2017-06-13       Impact factor: 7.561

Review 5.  Making vaccines "on demand": a potential solution for emerging pathogens and biodefense?

Authors:  Anne S De Groot; Leo Einck; Leonard Moise; Michael Chambers; John Ballantyne; Robert W Malone; Matthew Ardito; William Martin
Journal:  Hum Vaccin Immunother       Date:  2013-07-22       Impact factor: 3.452

Review 6.  Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.

Authors:  Sumit Joshi; Keerti Rawat; Narendra Kumar Yadav; Vikash Kumar; Mohammad Imran Siddiqi; Anuradha Dube
Journal:  Front Immunol       Date:  2014-08-22       Impact factor: 7.561

Review 7.  Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases.

Authors:  Frances E Terry; Leonard Moise; Rebecca F Martin; Melissa Torres; Nils Pilotte; Steven A Williams; Anne S De Groot
Journal:  Expert Rev Vaccines       Date:  2014-09-05       Impact factor: 5.217

8.  iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines.

Authors:  Leonard Moise; Andres Gutierrez; Farzana Kibria; Rebecca Martin; Ryan Tassone; Rui Liu; Frances Terry; Bill Martin; Anne S De Groot
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 9.  Post-Genomics and Vaccine Improvement for Leishmania.

Authors:  Negar Seyed; Tahereh Taheri; Sima Rafati
Journal:  Front Microbiol       Date:  2016-04-06       Impact factor: 5.640

10.  Designing a DNA Vaccine-based Leishmania major Polytope (Preliminary Report).

Authors:  Shabnam Jeibouei; Mojgan Bandehpour; Bahram Kazemi; Ali Haghighi
Journal:  Iran J Parasitol       Date:  2017 Jul-Sep       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.